Comparative pharmacokinetics of Kogenate FS and Kovaltry in 14 Chinese paediatric patients with haemophilia A: A single-centre study

被引：2
作者：
Huang, Kun [1 ]
Li, Gang [1 ]
Zhen, Yingzi [1 ]
Wu, Xinyi [1 ]
Chen, Zhenping [1 ]
Wu, Runhui [1 ]
机构：
[1] Capital Med Univ, Natl Key Discipline Pediat, Beijing Key Lab Pediat Hematol Oncol, Hematol Oncol Ctr,Beijing Childrens Hosp,Minist E, Beijing, Peoples R China
来源：
HAEMOPHILIA | 2021年 / 27卷 / 02期
关键词：
factor VIII; haemophilia A; haemorrhage; paediatric patients; pharmacokinetics; BAY; 81-8973; FACTOR-VIII; PLASMA;
D O I：
10.1111/hae.14163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E287 / E290
页数：4
相关论文
共 11 条
  • [1] Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients
    Blanchette, V. S.
    Shapiro, A. D.
    Liesner, R. J.
    Navarro, F. Hernandez
    Warrier, I.
    Schroth, P. C.
    Spotts, G.
    Ewenstein, B. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) : 1319 - 1326
  • [2] Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
    Chen, Zhen-Ping
    Li, Pei-Jing
    Li, Gang
    Tang, Ling
    Zhen, Ying-Zi
    Wu, Xin-Yi
    Cheng, Xiao-Ling
    Luke, Koon Hung
    Blanchette, Victor S.
    Poon, Man-Chiu
    Ding, Qiu-Lan
    Wu, Run-Hui
    [J]. CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1781 - U28
  • [3] Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
    Collins, P. W.
    Bjorkman, S.
    Fischer, K.
    Blanchette, V.
    Oh, M.
    Schroth, P.
    Fritsch, S.
    Casey, K.
    Spotts, G.
    Ewenstein, B. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) : 269 - 275
  • [4] Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate®) and BAY 81-8973 (KovaltryA®) in patients with severe or moderate haemophilia A in prophylaxis
    Eduardo Megias-Vericat, Juan
    Bonanad, Santiago
    Haya, Saturnino
    Rosa Cid, Ana
    Remedios Marques, Maria
    Monte-Boquet, Emilio
    Perez-Alenda, Sofia
    Bosch, Pau
    Querol, Felipe
    Luis Poveda, Jose
    [J]. HAEMOPHILIA, 2019, 25 (03) : E215 - E218
  • [5] BAY 81-8973 (Octocog Alfa; Kovaltry®): A Review in Haemophilia A
    Keating, Gillian M.
    [J]. BIODRUGS, 2016, 30 (05) : 453 - 459
  • [6] Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A
    Kepa, S.
    Horvath, B.
    Reitter-Pfoertner, S.
    Schemper, M.
    Quehenberger, P.
    Grundbichler, M.
    Heistinger, M.
    Neumeister, P.
    Mannhalter, C.
    Pabinger, I.
    [J]. HAEMOPHILIA, 2015, 21 (03) : 343 - 350
  • [7] LEE ML, 1993, THROMB HAEMOSTASIS, V69, P87
  • [8] Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII
    Shah, A.
    Delesen, H.
    Garger, S.
    Lalezari, S.
    [J]. HAEMOPHILIA, 2015, 21 (06) : 766 - 771
  • [9] Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
    Shah, Anita
    Solms, Alexander
    Garmann, Dirk
    Katterle, Yvonne
    Avramova, Verzhiniya
    Simeonov, Stanislav
    Lissitchkov, Toshko
    [J]. CLINICAL PHARMACOKINETICS, 2017, 56 (09) : 1045 - 1055
  • [10] Guidelines for the management of hemophilia
    Srivastava, A.
    Brewer, A. K.
    Mauser-Bunschoten, E. P.
    Key, N. S.
    Kitchen, S.
    Llinas, A.
    Ludlam, C. A.
    Mahlangu, J. N.
    Mulder, K.
    Poon, M. C.
    Street, A.
    [J]. HAEMOPHILIA, 2013, 19 (01) : E1 - E47
12